Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.
Animals
Antibodies, Viral
/ immunology
Batch Cell Culture Techniques
Bioreactors
Disease Models, Animal
Ebola Vaccines
/ administration & dosage
Ebolavirus
/ genetics
Female
HEK293 Cells
Hemorrhagic Fever, Ebola
/ immunology
Humans
Immunization
Mice
Vaccines, DNA
/ administration & dosage
Vesiculovirus
/ genetics
Ebola
HEK 293SF
Production
Serum-free
Suspension
Vaccine
rVSV-ZEBOV
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
16 10 2019
16 10 2019
Historique:
received:
01
08
2019
revised:
28
08
2019
accepted:
11
09
2019
pubmed:
25
9
2019
medline:
30
9
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
Ebola virus disease is an urgent international priority. Promising results for several vaccine candidates have been reported in non-human primate studies and clinical trials with the most promising being the rVSV-ZEBOV vaccine. In this study, we sought to produce rVSV-ZEBOV in HEK 293SF cells in suspension and serum-free media. The purpose of this study was to establish a process using the HEK 293SF production platform, optimise the production titre, demonstrate scalability and the efficiency of the generated material to elicit an immune reaction in an animal model. Critical process parameters were evaluated to maximize production yield and process robustness and the following operating conditions: 1-2 × 10
Identifiants
pubmed: 31548015
pii: S0264-410X(19)31253-8
doi: 10.1016/j.vaccine.2019.09.044
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Ebola Vaccines
0
Vaccines, DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6624-6632Subventions
Organisme : CIHR
ID : OVV 152411
Pays : Canada
Informations de copyright
Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.